Since the entry into force of the revised Therapeutic Products Act, Swissmedic has published additional information of general interest relating to therapeutic products. On the basis of Art. 67 para. 1 TPA and the implementing provisions of Art. 68 para. 1 let. e TPO, it publishes a SwissPAR summary evaluation report for all human medicinal products with a new active substance, as well as for transplant products, for which a decision to approve or reject authorisation has been issued. Swissmedic also publishes a supplementary report for approved or rejected applications relating to additional indications for human medicinal products for which a SwissPAR has been published following the new authorisation. The SwissPAR includes the evaluation results, but not the applicant's commercial or manufacturing secrets or personal data.
The SwissPAR is intended particularly for healthcare professionals, industry representatives and other national and international authorities. It is published in English only using specific technical terminology.
The following list also includes SwissPARs for medicinal products that are no longer authorised. These SwissPARs are indicated as “no longer authorised” in the relevant description. You can find an overview of currently authorised medicinal products here.
In addition to the full SwissPAR, Swissmedic publishes an abridged version of the SwissPAR known as the “Summary report on authorisation”. The Summary report is intended to make Swissmedic's authorisation decisions comprehensible and transparent to the wider public, and to give them access to relevant information on medicinal products.